ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
This study investigated whether human immunodeficiency virus type 1 (HIV-1) infected subjects
with raised cholesterol switching their nucleoside reverse transcriptase inhibitor (NRTI)
backbone from Kivexa (Epzicom) to Truvada had an improvement in their fasting total
cholesterol after 12 weeks of treatment. The study also investigated whether any improvement
had a beneficial effect on the overall cardiovascular risk.